Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma.
head and neck cancer
immune checkpoint
immune infiltrate
immunotherapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
received:
07
01
2021
revised:
16
02
2021
accepted:
25
02
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors usually diagnosed at an advanced stage and characterized by a poor prognosis. The main risk factors associated with its development include tobacco and alcohol consumption and Human Papillomavirus (HPV) infections. The immune system has a significant role in the oncogenesis and evolution of this cancer type. Notably, the immunosuppressive tumor microenvironment triggers immune escape through several mechanisms. The improved understanding of the antitumor immune response in solid tumors and the role of the immune checkpoint molecules and other immune regulators have led to the development of novel therapeutic strategies that revolutionized the clinical management of HNSCC. However, the limited overall response rate to immunotherapy urges identifying predictive biomarkers of response and resistance to treatment. Here, we review the role of the immune system and immune checkpoint pathways in HNSCC, the most relevant clinical findings linked to immunotherapeutic strategies and predictive biomarkers of response and future treatment perspectives.
Identifiants
pubmed: 33804419
pii: cancers13051018
doi: 10.3390/cancers13051018
pmc: PMC7957692
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Agencia Nacional de Promoción Científica y Tecnológica
ID : PICT 2014-3687
Organisme : Agencia Nacional de Promoción Científica y Tecnológica
ID : 2017-0494
Organisme : Agencia Nacional de Promoción Científica y Tecnológica
ID : 2016-2130
Organisme : Grupo Español de Melanoma
ID : N/A
Organisme : Instituto Nacional del Cancer
ID : N/A
Organisme : Richard Lounsbery Foundation
ID : N/A
Organisme : Fundación Sales
ID : N/A
Organisme : Fundación Bunge & Born
ID : N/A
Références
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Cancer. 2008 Aug 15;113(4):750-7
pubmed: 18536030
Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75
pubmed: 15734974
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
Cancer Res. 2012 Dec 1;72(23):6097-101
pubmed: 23172309
J Immunother Cancer. 2019 Jul 23;7(1):193
pubmed: 31337439
Nat Cell Biol. 2020 Sep;22(9):1064-1075
pubmed: 32839551
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Cancer Res. 2006 Sep 15;66(18):9281-9
pubmed: 16982773
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Clin Cancer Res. 2002 Aug;8(8):2553-62
pubmed: 12171883
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cancer Immunol Immunother. 2007 Oct;56(10):1645-52
pubmed: 17387473
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Oral Oncol. 2019 Jun;93:66-75
pubmed: 31109698
Neoplasia. 2001 Jan-Feb;3(1):53-61
pubmed: 11326316
Ann Oncol. 2020 Sep;31(9):1115-1118
pubmed: 32771306
Front Oncol. 2019 Aug 29;9:827
pubmed: 31555588
Cytokine. 2004 Mar 7;25(5):220-8
pubmed: 15036248
Nat Rev Clin Oncol. 2018 Jun;15(6):382-396
pubmed: 29636538
Clin Cancer Res. 2005 Feb 15;11(4):1434-40
pubmed: 15746043
Hum Gene Ther Clin Dev. 2013 Sep;24(3):134-42
pubmed: 24099518
Clin Cancer Res. 2018 Oct 1;24(19):4834-4844
pubmed: 29914893
Br J Cancer. 2013 Nov 12;109(10):2629-35
pubmed: 24169351
N Engl J Med. 2001 Apr 12;344(15):1125-31
pubmed: 11297703
J Exp Clin Cancer Res. 2018 Mar 5;37(1):44
pubmed: 29506555
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Annu Rev Pathol. 2009;4:49-70
pubmed: 18729723
Ann Oncol. 2019 Jan 1;30(1):68-75
pubmed: 30407504
Ann Oncol. 2020 Jul;31(7):942-950
pubmed: 32294530
Clin Cancer Res. 2018 Feb 15;24(4):896-905
pubmed: 29233903
J Clin Oncol. 2005 Dec 10;23(35):8932-41
pubmed: 16219933
Front Oncol. 2019 Jul 23;9:656
pubmed: 31396482
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Cancer Res. 2016 Mar 1;76(5):1031-43
pubmed: 26676749
Cancer Med. 2020 Jan;9(2):640-652
pubmed: 31800160
Oncotarget. 2017 Jun 15;8(37):60860-60874
pubmed: 28977830
Elife. 2019 Nov 26;8:
pubmed: 31767055
Oncoimmunology. 2018 Jul 30;7(10):e1498439
pubmed: 30288365
Mod Pathol. 2020 Aug 5;:
pubmed: 32759978
Science. 2015 Apr 3;348(6230):80-6
pubmed: 25838377
Head Neck. 2008 Sep;30(9):1175-81
pubmed: 18642283
Nat Rev Cancer. 2011 Jan;11(1):9-22
pubmed: 21160525
Immunity. 2020 Jan 14;52(1):17-35
pubmed: 31940268
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
J Immunother Cancer. 2017 Aug 15;5(1):65
pubmed: 28806909
Clin Cancer Res. 2006 Jan 15;12(2):465-72
pubmed: 16428488
Clin Cancer Res. 2020 Mar 15;26(6):1420-1431
pubmed: 31848188
J Thorac Oncol. 2020 Sep;15(9):1449-1459
pubmed: 32389639
Am Soc Clin Oncol Educ Book. 2020 May;40:e275-e291
pubmed: 32453632
Clin Cancer Res. 2020 Jan 1;26(1):290-300
pubmed: 31562203
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
J Natl Cancer Inst. 2007 May 16;99(10):777-89
pubmed: 17505073
Genome Biol. 2018 Dec 3;19(1):211
pubmed: 30509292
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
JAMA Oncol. 2019 Jul 18;:
pubmed: 31318407
J Clin Invest. 2019 Dec 2;129(12):5553-5567
pubmed: 31710313
Cancer Treat Rev. 2020 Mar;84:101977
pubmed: 32018128
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
BMC Genomics. 2016 Jan 08;17:38
pubmed: 26747525
Mol Oncol. 2017 Feb;11(2):235-247
pubmed: 28102051
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
J Clin Oncol. 2020 Aug 1;38(22):2552-2557
pubmed: 32496903
Clin Cancer Res. 2002 Oct;8(10):3137-45
pubmed: 12374681
Science. 2018 Oct 12;362(6411):
pubmed: 30309915
Oncogene. 2010 Oct 7;29(40):5437-46
pubmed: 20676130
Clin Cancer Res. 2020 Mar 15;26(6):1474-1485
pubmed: 31848186
Cancer Immunol Res. 2019 Oct;7(10):1700-1713
pubmed: 31387897
N Engl J Med. 2007 Dec 20;357(25):2552-61
pubmed: 18094376
JAMA Oncol. 2019 Jan 1;5(1):67-73
pubmed: 30267032
Cancer Immunol Res. 2015 Apr;3(4):412-23
pubmed: 25691328
Clin Cancer Res. 2020 Oct 1;26(19):5140-5152
pubmed: 32665297
Nat Rev Immunol. 2020 Apr;20(4):209-215
pubmed: 31965064
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
Mod Pathol. 2017 Jan;30(s1):S104-S111
pubmed: 28060367
Science. 2018 Jan 5;359(6371):97-103
pubmed: 29097493
Cancers (Basel). 2019 Feb 15;11(2):
pubmed: 30781400
Cell Rep. 2017 Jan 3;18(1):248-262
pubmed: 28052254
Cancer Res. 2007 Sep 15;67(18):8865-73
pubmed: 17875728
Semin Oncol. 2010 Oct;37(5):473-84
pubmed: 21074063
Oncotarget. 2017 Mar 21;8(12):19310-19322
pubmed: 28038471
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Cancer Cell Int. 2018 Aug 28;18:120
pubmed: 30181713
J Clin Oncol. 2018 Nov 1;36(31):3152-3161
pubmed: 30188786
Future Oncol. 2019 Mar;15(7):687-694
pubmed: 30461306
Oncoimmunology. 2016 Mar 10;5(6):e1151594
pubmed: 27471622
J Immunol. 2008 May 1;180(9):5916-26
pubmed: 18424711
J Natl Cancer Inst. 2018 Dec 1;110(12):1386-1392
pubmed: 29659925
Cancers Head Neck. 2020 Mar 16;5:4
pubmed: 32195008
Br J Cancer. 2019 May;120(10):1003-1006
pubmed: 30967647
Oncoimmunology. 2016 Jan 19;5(5):e1130206
pubmed: 27467947
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4345-54
pubmed: 17671115
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Clin Cancer Res. 2007 Jun 1;13(11):3182-90
pubmed: 17545521
Oncoimmunology. 2019 Apr 24;8(7):1593805
pubmed: 31143513
Lancet. 2019 Jan 12;393(10167):156-167
pubmed: 30509740
Cell. 2017 Dec 14;171(7):1611-1624.e24
pubmed: 29198524
Oral Oncol. 2019 Apr;91:47-55
pubmed: 30926062
JCI Insight. 2016 Oct 20;1(17):e89829
pubmed: 27777979
Cancer Res. 2015 Jun 1;75(11):2200-10
pubmed: 25832655
Clin Cancer Res. 2018 Nov 1;24(21):5368-5380
pubmed: 30042205
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
J Natl Compr Canc Netw. 2020 Jul;18(7):899-906
pubmed: 32634775
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
JAMA Oncol. 2018 Mar 1;4(3):358-365
pubmed: 29327043
Sci Rep. 2017 Dec 15;7(1):17686
pubmed: 29247187
Ann Oncol. 2020 Nov;31(11):1462-1475
pubmed: 33239190
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
J Immunol. 2006 Mar 15;176(6):3402-9
pubmed: 16517708
Nat Commun. 2019 Dec 5;10(1):5546
pubmed: 31804466
Cancer Immunol Immunother. 2006 Feb;55(2):151-9
pubmed: 15889251
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Cancer Res. 2008 Jun 15;14(12):3706-15
pubmed: 18559587
J Immunol. 2002 Nov 15;169(10):5392-5
pubmed: 12421911
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Ann Oncol. 2018 Jan 1;29(1):71-83
pubmed: 29069302
J Immunother. 1998 Jul;21(4):295-306
pubmed: 9672851
Oncoimmunology. 2016 Oct 7;5(11):e1239005
pubmed: 27999760
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Int J Cancer. 2016 Jul 1;139(1):122-9
pubmed: 26888626
Oncotarget. 2016 Mar 29;7(13):15901-14
pubmed: 26893364
PLoS One. 2015 Jun 12;10(6):e0129119
pubmed: 26066796
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Cancer Cell. 2020 Nov 9;38(5):685-700.e8
pubmed: 33007259
Science. 1996 Mar 22;271(5256):1734-6
pubmed: 8596936
Future Oncol. 2020 Jun;16(18):1235-1243
pubmed: 32490686